Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07863295
ABSTRACT:
Small fiber neuropathy is treated by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions.
REFERENCES:
patent: 5976547 (1999-11-01), Archer et al.
patent: 6413982 (2002-07-01), Yuan et al.
patent: 2004/0192728 (2004-09-01), Codd et al.
Tokugawa, K. et al., “XIB4035, A Novel Nonpeptidyl Small Molecule Agonist for GFRAlpha-2”, Neurochemistry International, 2003, vol. 42, pp. 81-86. see abstract.
Akkina, S.K. et al., “GDNF Rescures Nonpeptidergic Unmyelinated Primary Afferents in Streptozotocin-Treated Diabetic Mice”, Experimental Neurology, 2001, vol. 167, pp. 173-182.
ISA, International Search Report & Written Opinion, in PCT/US2009/032910.
Corfas Gabriel
Murtie Joshua C.
Children's Medical Center Corporation
Osman Richard Aron
Spivack Phyllis G.
LandOfFree
Treatments for neuropathy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatments for neuropathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatments for neuropathy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2715032